References
- Bianconi SE, Cross JL, Wassif CA, Porter FD. Pathogenesis, epidemiology, diagnosis and clinical aspects of Smith-Lemli-Opitz syndrome. Expert Opin Orphan Drugs. 2015; 3(3): 267-280.
- Witsch-Baumgartner M, Löffler J, Utermann G. Mutations in the human DHCR7 gene. Hum Mutat. 2001; 17(3): 172-182.
- DeBarber AE, Eroglu Y, Merkens LS, Pappu AS, Steiner RD. Smith-Lemli-Opitz syndrome. Expert Rev Mol Med. 2011; 13: e24.
- Svoboda MD, Christie JM, Eroglu Y, Freeman KA, Steiner RD. Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 285-294.
- Waterham HR, Hennekam RCM. Mutational spectum of Smith-Lemli-Opitz syndrome. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 263-284.
- Ballout RA, Bianconi S, Livinski A, Fu Y-P, Remaley AT, Porter FD. Statins for Smith-Lemli-Opitz syndrome. Cochrane Libr. 2020; 2020(1): CD013521.
- Ertugrul G, Yankol Y, Mecit N, Kirimlioglu H, Kanmaz T, Acarli K, et al. Liver transplant and improvements in cholesterol biosynthesis defects: A case report of Smith-Lemli-Opitz syndrome. Exp Clin Transplant. 2019 Jan 21. doi: 10.6002/ect.2018.0131.Onlineaheadofprint.
- Eroglu Y, Nguyen-Driver M, Steiner RD, Merkens L, Merkens M, Roullet J-B, et al. Normal IQ is possible in Smith-Lemli-Opitz syndrome. Am J Med Genet A. 2017; 173(8): 2097-2100.